Cellectar BioSciences Inc. reported a net loss attributable to common stockholders of $4.4 million, or $1.41 per basic and diluted share, for the third quarter ended September 30, 2025. This compares to a net loss of $14.7 million, or $11.18 per basic and $12.13 per diluted share, for the same period in 2024. General and administrative expenses were approximately $2.3 million, down from $7.8 million in the prior year period, mainly due to lower commercialization and personnel costs. During the quarter, the company confirmed eligibility to submit for conditional marketing authorization for iopofosine I-131 in Waldenstrom's Macroglobulinemia in Europe in 2026, initiated a Phase 1b study of CLR 125 for triple-negative breast cancer, and received rare pediatric drug designation for iopofosine I-131 in inoperable relapsed/refractory pediatric high-grade glioma.